CDKN1A and breast carcinoma: We additionally tested the effect of pharmacological inhibition of p21 on the susceptibility of breast cancer cell lines to abemaciclib and/or ABT‐263 in vitro and found that a p21 inhibitor UC228829 sensitized them to ABT‐263 (Figure S5).